Is MIPS 7 the same as MIPS 007?

Yes. CMS uses zero-padded three-digit Quality IDs (007) in official specifications, while clinicians often search for MIPS 7 or Quality ID 7 without the leading zero. Both refer to the same 2026 MIPS quality measure reported through the Quality Payment Program (QPP).

What codes do I submit for MIPS 007: Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial?

Submission codes: G9189 (Beta-blocker therapy prescribed or currently being taken); 4008F (Beta-blocker therapy prescribed or currently being taken); G9188 (Beta-blocker therapy not prescribed, reason not given); 4008F with 8P (Beta-blocker therapy not prescribed, reason not otherwise specified)

What is the NQF number for MIPS Measure 007?

MIPS Measure 007 is associated with CBE/NQF number 70. It is also identified as eCQM CMS145v14. It can be reported through the Quality Payment Program (QPP) as a MIPS Clinical Quality Measure (CQM).

How do I report MIPS Measure 007 in 2026?

MIPS Measure 007 (Quality ID 7) is reported through the Quality Payment Program (QPP) as a MIPS Clinical Quality Measure (CQM) via qualified registry, eCQM, or Medicare Part B claims where applicable.

Is MIPS 007 a topped-out measure?

Yes, MIPS 007 is currently topped out, which means most clinicians perform well on this measure and it may be subject to a 7-point scoring cap.

Measure ID: MIPS 007|Cardiology|2026 Performance Year

2026 MIPS Measure #007: Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior LVEF ≤ 40% who were prescribed beta-blocker therapy.

ProcessCardiologyMedication Management

Measure ID:MIPS 007 (Quality ID 7)

eCQM:CMS145v14

CBE:70

Collection:MIPS CQM, eCQM

Topped Out:Yes

View CMS Spec ↗

Measure Specification

This measure produces 2 performance rates. Each rate has its own eligible population, numerator, and reporting codes.

Rate 1

Eligible Population

Patients aged ≥ 18 years on date of encounter

ANDDiagnosis for coronary artery disease on date of encounter

ORHistory of cardiac surgery

ANDPatient encounter during performance period – to be used for numerator evaluation

ANDAt least one additional patient encounter during performance period

ANDCurrent or prior left ventricular ejection fraction (LVEF) ≤ 40% or documentation of moderate or severe LVSD: G8694

Exclusions

None

Numerator

Patients who were prescribed beta-blocker therapy.

Reporting Codes

Performance Met:

G9189Beta-blocker therapy prescribed or currently being taken

Performance Not Met:

G9188Beta-blocker therapy not prescribed, reason not given

○ Exceptions:

G9190Documentation of medical reason(s) for not prescribing beta-blocker therapy (e.g., allergy, intolerance, other medical reasons)

G9191Documentation of patient reason(s) for not prescribing beta-blocker therapy (e.g., patient declined, other patient reasons)

Rate 2

Eligible Population

ORAll patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have prior (within the past 3 years) MI

ANDDiagnosis for coronary artery disease on date of encounter

ORHistory of cardiac surgery

ANDDiagnosis for myocardial infarction – includes patient that had a prior (within the past 3 years) myocardial infarction

ANDPatient encounter during performance period – to be used for numerator evaluation

ANDAt least one additional patient encounter during performance period

Exclusions

None

Reporting Codes

Performance Met:

4008FBeta-blocker therapy prescribed or currently being taken

Performance Not Met:

4008F with 8PBeta-blocker therapy not prescribed, reason not otherwise specified

○ Exceptions:

Documentation of medical reason(s) for not prescribing beta- blocker therapy (e.g., allergy, intolerance, other medical reasons) (4008F with 1P)

Documentation of patient reason(s) for not prescribing beta- blocker therapy (e.g., patient declined, other patient reasons) (4008F with 2P)

VBCA Insights

Why This Measure Matters

This measure ensures patients with coronary artery disease who have had a heart attack or have weakened heart function are on beta-blockers, which reduce chest pain and lower mortality risk. Beta-blockers are lifesaving in this population, particularly after MI or when ejection fraction is reduced. Prescribe cardioselective beta-blockers early and maintain them long-term unless contraindicated. Dose optimization and adherence monitoring are important for maximizing benefit.

VBCA is a CMS-approved Qualified Clinical Data Registry (QCDR) that submits MIPS Measure 007 to the Quality Payment Program (QPP). Practices can report this measure as a MIPS Clinical Quality Measure (CQM), as an eCQM, or through qualified registry submission.

🧮MIPS Score Simulator

Estimate only — actual CMS scoring may vary based on reporting method, data completeness, and annual rule updates.

Your Performance Rate:%Benchmarks vary by collection type

💡 Tip: Enter your performance rate to compare MIPS points across all collection types. The same rate can score differently depending on how you submit.

Specialty Measure Sets

Cardiology Family Medicine Internal Medicine Skilled Nursing Facility

Related Measures

Cardiology

MIPS 006: Coronary Artery Disease (CAD): Antiplatelet Therapy MIPS 118: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE)MIPS 326: Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy MIPS 438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease MIPS 441: Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control)

Medication Management

MIPS 005: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or MIPS 008: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic MIPS 118: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE)MIPS 130: Documentation of Current Medications in the Medical Record MIPS 180: Rheumatoid Arthritis (RA): Glucocorticoid Management MIPS 268: Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy MIPS 410: Psoriasis: Clinical Response to Systemic Medications MIPS 468: Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)MIPS 489: Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or MIPS 490: Appropriate Intervention of Immune-Related Diarrhea and/or Colitis in Patients Treated

Official Resources

📄 CMS Measure Specification (PDF)🔗 QPP Quality Payment Program

Clinical Rationale

For patients with coronary artery disease (CAD), beta-blockers are recommended for 3 years after myocardial infarction or acute coronary syndrome. Beta-blockers, particularly carvedilol, metoprolol succinate, or bisoprolol, which have been shown to reduce risk of death, are recommended indefinitely for patients with CAD and LV systolic dysfunction.

These agents have proven efficacy in reducing angina onset and improving the ischemic threshold during exercise. In patients who have suffered an MI, beta-blockers significantly reduce deaths and recurrent MIs. Nonadherence to cardio protective medications is prevalent among outpatients with CAD and can be associated with a broad range of adverse outcomes, including all-cause and cardiovascular mortality, cardiovascular hospitalizations, and the need for revascularization procedures.

This measure is intended to promote beta-blocker usage in select patients with CAD.

Clinical Recommendations

Beta-blocker therapy should be started and continued for 3 years in all patients with normal LV function after MI or ACS. (Class I, Level of Evidence: B) (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS, 2012). Beta-blocker therapy should be used in all patients with LV systolic dysfunction (EF ≤ 40%) with heart failure or prior MI, unless contraindicated. (Use should be limited to carvedilol, metoprolol succinate, or bisoprolol, which have been shown to reduce risk of death.

) (Class I, Level of Evidence: A) (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS, 2012). In patients with CCD and LVEF ≤ 40% with or without previous MI, the use of beta-blocker therapy is recommended to reduce the risk of future MACE, including cardiovascular death.

Implementation Notes

This measure contains two strata defined by two submission criteria. This measure produces a single performance rate using a weighted average. There are 2 Submission Criteria for this measure: 1) All patients with a diagnosis of CAD or history of cardiac surgery who have a current or prior LVEF ≤ 40% OR 2) All patients with a diagnosis of CAD or history of cardiac surgery who have a prior (within the past 3 years) MI Only patients who had at least two denominator eligible visits during the performance period will be counted for Submission Criteria 1 and Submission Criteria 2 of this measure.

The MIPS eligible clinician should submit data on one of the submission criteria, depending on the clinical findings. If the patient has CAD or history of cardiac surgery and a current or prior LVEF ≤ 40% (or moderate or severe LVSD), use Submission Criteria 1. If the patient has CAD or history of cardiac surgery and has a prior (within the past 3 years) MI, use Submission Criteria 2.

The 3-year lookback period for the prior MI should be from the time of the encounter that is used to qualify for the denominator and evaluate the numerator. If the patient has had an MI within the past 3 years and has a current or prior LVEF ≤ 40% (or moderate or severe LVSD), the MIPS eligible clinician should submit quality data codes for Submission Criteria 1 and this will count as appropriate submission for this patient.

Report this measure through VBCA

Our QCDR handles measure selection, data validation, and submission—so you can focus on clinical performance.

Learn About Our QCDR →Talk to Us